Literature DB >> 3919095

Interferons as macrophage-activating factors. III. Preferential effects of interferon-gamma on the interleukin 1 secretory potential of fresh or aged human monocytes.

F Arenzana-Seisdedos, J L Virelizier, W Fiers.   

Abstract

Human peripheral blood adherent leukocytes incubated with interferon (IFN) of three different species (alpha, beta, or gamma) show an enhanced potential of IL 1 synthesis and secretion that can be revealed by a second signal provided by endotoxins or Poly IC. We have shown that recombinant IFN-gamma, compared with recombinant IFN-alpha or purified IFN-beta, has preferential effects on IL 1 secretion in fresh monocyte cultures. We have observed a progressive and profound loss of the ability of adherent cell cultures to secrete IL 1 upon aging for 4 to 12 days in vitro. IFN-gamma was found to be more efficient than IFN-alpha or -beta at maintaining (when added at the onset of the cultures) or reversing the loss (when added on the fourth day of culture) of the IL 1 secretory function. These observations suggest that the secretion of IFN-gamma during the course of immune responses may have a critical role in feeding back the cascade of interleukins in a loop of amplification, and may thereby regulate macrophage-T lymphocyte interactions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919095

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Mediators of ischemia-reperfusion injury of rat lung.

Authors:  M J Eppinger; G M Deeb; S F Bolling; P A Ward
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Involvement of gamma interferon in antibody enhancement by adjuvants.

Authors:  M J Odean; C M Frane; M Van derVieren; M A Tomai; A G Johnson
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

3.  Cytokine production in patients with inflammatory bowel disease.

Authors:  M Nakamura; H Saito; J Kasanuki; Y Tamura; S Yoshida
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

4.  Effect of interferon-gamma priming on the activation of murine peritoneal macrophages to tumouricidal state by cisplatin, IL-1, and tumour necrosis factor (TNF): production of IL-1 and TNF.

Authors:  A Sodhi; R K Singh; S M Singh
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

5.  Differential effects of LPS, IFN-gamma and TNF alpha on the secretion of lysozyme by individual human mononuclear phagocytes: relationship to cell maturity.

Authors:  C E Lewis; S P McCarthy; J Lorenzen; J O McGee
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

6.  Interferon gamma drastically modifies the regulation of interleukin 1 genes by endotoxin in U937 cells.

Authors:  C Ucla; P Roux-Lombard; S Fey; J M Dayer; B Mach
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

7.  Natural killing of fibroblasts infected with low-passage clinical isolates of human cytomegalovirus.

Authors:  S Bandyopadhyay; S H Oh; S Michelson; D S Miller; J L Virelizier; S E Starr
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

8.  Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1 beta concentrations in anaemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukaemia (HEL) cells in vitro.

Authors:  C P Maury; L C Andersson; A M Teppo; S Partanen; E Juvonen
Journal:  Ann Rheum Dis       Date:  1988-12       Impact factor: 19.103

9.  Stably expressed antisense RNA to cytomegalovirus UL83 inhibits viral replication.

Authors:  P Dal Monte; C Bessia; A Ripalti; M P Landini; A Topilko; B Plachter; J L Virelizier; S Michelson
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Identification of immunological parameters associated with the alveolar bone level in periodontal patients.

Authors:  Chang-Seo Park; Ju-Yeon Lee; Sung-Jo Kim; Jeom-Il Choi
Journal:  J Periodontal Implant Sci       Date:  2010-04-15       Impact factor: 2.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.